RARE (STOCKS)
Ultragenyx Pharmaceutical Inc.
$26.000000
+1.650000 (+6.78%)
Prev close: $24.350000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Emil D. Kakkis
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,498.67M
- Employees
- 1,294
- P/E (TTM)
- -4.16
- P/B (TTM)
- -10.54
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
14
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-1.84 | $-1.54 | -0.3001 | -19.49% |
|
Dec 2025 (Q4)
|
$-1.29 | $-1.11 | -0.1762 | -15.82% |
|
Sep 2025 (Q3)
|
$-1.81 | $-1.26 | -0.5508 | -43.74% |
|
Jun 2025 (Q2)
|
$-1.17 | $-1.32 | +0.1547 | +11.68% |
Financial Statements
| Revenues | $669.71M |
| Benefits Costs and Expenses | $1.27B |
| Costs And Expenses | $1.27B |
| Operating Expenses | $1.23B |
| Selling, General, and Administrative Expenses | $349.20M |
| Research and Development | $771.23M |
| Other Operating Expenses | $110.34M |
| Operating Income/Loss | -$561.06M |
| Income/Loss From Continuing Operations After Tax | -$608.92M |
| Income/Loss From Continuing Operations Before Tax | -$605.23M |
| Income Tax Expense/Benefit | $3.69M |
| Net Income/Loss | -$608.92M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$608.92M |
| Net Income/Loss Available To Common Stockholders, Basic | -$608.92M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$6.10 |
| Diluted Earnings Per Share | -$6.10 |
| Basic Average Shares | 299,245,309 |
| Diluted Average Shares | 299,245,309 |
| Assets | $1.30B |
| Current Assets | $657.00M |
| Inventory | $55.00M |
| Other Current Assets | $602.00M |
| Noncurrent Assets | $639.00M |
| Fixed Assets | $239.00M |
| Intangible Assets | $174.00M |
| Other Non-current Assets | $226.00M |
| Liabilities | $1.53B |
| Current Liabilities | $325.00M |
| Accounts Payable | $42.00M |
| Wages | $57.00M |
| Other Current Liabilities | $226.00M |
| Noncurrent Liabilities | $1.20B |
| Equity | -$236.00M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$236.00M |
| Temporary Equity | $7.00M |
| Liabilities And Equity | $1.30B |
| Net Cash Flow From Operating Activities | -$497.00M |
| Net Cash Flow From Operating Activities, Continuing | -$497.00M |
| Net Cash Flow From Investing Activities | $67.00M |
| Net Cash Flow From Investing Activities, Continuing | $67.00M |
| Net Cash Flow From Financing Activities | $723.84M |
| Net Cash Flow From Financing Activities, Continuing | $678.00M |
| Net Cash Flow | $248.00M |
| Net Cash Flow, Continuing | $248.00M |
| Comprehensive Income/Loss | -$608.22M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$608.22M |
| Other Comprehensive Income/Loss | $698.00K |